OIM
AXDX

Oracle Investment Management’s Accelerate Diagnostics AXDX Stock Holding History

Oracle Investment Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-42,101
Closed -$41.7K – 23
2024
Q1 		$41.7K Sell
42,101
-69,474
-62% -$110K 0.03% 26
2023
Q4 		$437K Sell
111,575
-24,953
-18% -$132K 0.27% 22
2023
Q3 		$785K Sell
136,528
-14,537
-10% -$97.8K 0.24% 16
2023
Q2 		$1.22M Hold
151,065
– – 0.9% 18
2023
Q1 		$1.06M Sell
151,065
-11,743
-7% -$70.6K 1.02% 15
2022
Q4 		$1.15M Sell
162,808
-58,079
-26% -$634K 0.96% 14
2022
Q3 		$3.36M Sell
220,887
-23,692
-10% -$392K 1.91% 10
2022
Q2 		$2.43M Sell
244,579
-28,607
-10% -$253K 0.74% 14
2022
Q1 		$3.93M Sell
273,186
-89,569
-25% -$2.55M 0.78% 14
2021
Q4 		$18.9M Sell
362,755
-12,357
-3% -$688K 2.69% 9
2021
Q3 		$21.9M Sell
375,112
-2,500
-0.7% -$163K 2.72% 9
2021
Q2 		$30.4M Hold
377,612
– – 4.19% 8
2021
Q1 		$31.4M Sell
377,612
-3,002
-0.8% -$305K 4.7% 7
2020
Q4 		$28.9M Sell
380,614
-28,561
-7% -$2.56M 3.62% 7
2020
Q3 		$43.6M Buy
409,175
+2,281
+0.6% +$317K 5.75% 5
2020
Q2 		$61.7M Sell
406,894
-3,335
-0.8% -$329K 7.83% 3
2020
Q1 		$34.2M Sell
410,229
-11,086
-3% -$1.56M 10.15% 3
2019
Q4 		$71.2M Sell
421,315
-13,499
-3% -$2.23M 13.37% 4
2019
Q3 		$80.7M Sell
434,814
-822
-0.2% -$159K 19.86% 2
2019
Q2 		$99.7M Buy
435,636
+680
+0.2% +$133K 21.44% 2
2019
Q1 		$91.4M Buy
434,956
+15,154
+4% +$2.84M 19.45% 3
2018
Q4 		$48.3M Buy
419,802
+1,087
+0.3% +$161K 14.97% 3
2018
Q3 		$96.1M Sell
418,715
-8,693
-2% -$1.92M 21.04% 2
2018
Q2 		$95.3M Sell
427,408
-17,354
-4% -$3.88M 23.04% 2
2018
Q1 		$102M Sell
444,762
-16,972
-4% -$4.46M 24.62% 2
2017
Q4 		$121M Sell
461,734
-8,930
-2% -$2.09M 24.04% 1
2017
Q3 		$106M Sell
470,664
-1,289
-0.3% -$317K 17.33% 4
2017
Q2 		$129M Hold
471,953
– – 20.39% 2
2017
Q1 		$114M Sell
471,953
-31,286
-6% -$7.15M 17.81% 2
2016
Q4 		$104M Sell
503,239
-6,034
-1% -$1.43M 17.32% 2
2016
Q3 		$139M Buy
509,273
+527
+0.1% +$117K 21.39% 1
2016
Q2 		$73.2M Buy
508,746
+4,971
+1% +$667K 17.04% 1
2016
Q1 		$72.4M Sell
503,775
-60,579
-11% -$8.55M 18.82% 1
2015
Q4 		$121M Buy
564,354
+21,765
+4% +$3.97M 21.01% 1
2015
Q3 		$87.8M Hold
542,589
– – 17.96% 1
2015
Q2 		$140M Hold
542,589
– – 16.99% 1
2015
Q1 		$122M Hold
542,589
– – 15.49% 1
2014
Q4 		$104M Hold
542,589
– – 13.65% 1
2014
Q3 		$117M Buy
542,589
+3,183
+0.6% +$619K 16.12% 1
2014
Q2 		$140M Buy
539,406
+61,601
+13% +$13.4M 17.02% 1
2014
Q1 		$104M Buy
477,805
+2,946
+0.6% +$437K 11.9% 1
2013
Q4 		$57.9M Buy
474,859
+9,408
+2% +$1.26M 7.97% 5
2013
Q3 		$62.4M Buy
465,451
+51,475
+12% +$4.59M 8.9% 5
2013
Q2 		$33.6M Buy
+413,976
New +$30.7M 5.8% 7

Other funds holding AXDX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oracle Investment Management's AXDX Position: Q2 2024 in Review

Oracle Investment Management sold out of Accelerate Diagnostics (AXDX) in Q2 2024, closing a stake of 42,101 shares — an estimated $41.7K sold.

Oracle Investment Management first reported a position in AXDX in Q2 2013 and held it in 44 quarters. The position peaked at $140M in Q2 2014. 41 funds tracked by Wall St. Rank hold AXDX as of Q2 2024.

  • Oracle Investment Management reported no remaining Accelerate Diagnostics position as of Q2 2024 after selling out during the quarter.
  • Oracle Investment Management sold 42,101 Accelerate Diagnostics shares in Q2 2024, an estimated $41.7K.
  • Oracle Investment Management first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 44 quarters.
  • Oracle Investment Management's Accelerate Diagnostics position peaked at $140M in Q2 2014.
  • 41 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2024.

Based on Oracle Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.